Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06), Zacks reports.
Corvus Pharmaceuticals Price Performance
Shares of Corvus Pharmaceuticals stock traded down $0.27 during trading on Tuesday, reaching $3.98. 959,178 shares of the company traded hands, compared to its average volume of 564,653. The firm has a market capitalization of $255.74 million, a PE ratio of -4.28 and a beta of 0.91. The company has a 50 day moving average price of $4.72 and a 200-day moving average price of $6.10. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.38.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also
- Five stocks we like better than Corvus Pharmaceuticals
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Overbought Stocks Explained: Should You Trade Them?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- What is the S&P 500 and How It is Distinct from Other Indexes
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
